Know What's Happening in BioTech

Approve Longevity Drugs for Disease First, Then Expand to Aging
SocialMar 15, 2026

Approve Longevity Drugs for Disease First, Then Expand to Aging

The only sustainable path to development of longevity therapeutics is to get the potential longevity drug approved for a disease, then go for indication expansion and study it in the context of aging at different doses and regimens. To be...

By Alex Zhavoronkov, PhD
Consumer Biotech Will Eclipse Tech, Health Is Ultimate Value
SocialMar 15, 2026

Consumer Biotech Will Eclipse Tech, Health Is Ultimate Value

Consumer biotech will ultimately be bigger than consumer tech. What’s more valuable to people than health and wellness?

By Jason Kelly
Rethinking Where Patient Recruitment Begins
NewsMar 15, 2026

Rethinking Where Patient Recruitment Begins

Clinical trials have long relied on site‑based recruitment, leaving under‑ and misdiagnosed patients underrepresented. Recent studies show digital outreach can identify symptomatic individuals who never enter traditional healthcare pathways, dramatically expanding the eligible pool. Digital campaigns have cut cost per...

By MedCity News
Deconstructing Psychedelics to Engineer Non‑Hallucinogenic Therapies
SocialMar 15, 2026

Deconstructing Psychedelics to Engineer Non‑Hallucinogenic Therapies

How do you break psychedelic molecules into parts, like cars in a chop shop, and build new ones? A look into non-psychedelic psychedelic medicine by Clayton Dalton, an ER doc and Ferriss-UC Berkeley Psychedelic Journalism Fellow @ucbsoj & @SciPsychedelics https://t.co/b7R4aTNdyf

By Michael Pollan
AI Converts Standard Slides Into Spatial Proteomics, Cutting Costs
SocialMar 15, 2026

AI Converts Standard Slides Into Spatial Proteomics, Cutting Costs

We’ve trained a multimodal AI model to turn routine pathology slides into spatial proteomics, with the potential to reduce time and cost while expanding access to cancer care. https://t.co/OCptXdsUm1

By Satya Nadella
New Planctomycete Species Discovered Underground
NewsMar 15, 2026

New Planctomycete Species Discovered Underground

Researchers have isolated and described a new planctomycete, Anatilimnocola aquadivae sp. nov., from deep subsurface percolate samples. Comprehensive phenotypic, electron‑microscopic, and genomic analyses place it within the Pirellulaceae family but as a distinct lineage. The genome encodes anaerobic respiration, aromatic‑compound...

By Bioengineer.org
Never Trust Bulk RNA‑seq without These 7 QC Checks
SocialMar 15, 2026

Never Trust Bulk RNA‑seq without These 7 QC Checks

1/9 Every bulk RNA-seq experiment I run goes through the same 7 checks before I trust the results. I've been burned enough times to know: if you skip QC, you will find out the hard way. Usually during a meeting with...

By Ming Tang
Regulators, Not Pharma, Block Self‑Testing Experimental Therapies
SocialMar 15, 2026

Regulators, Not Pharma, Block Self‑Testing Experimental Therapies

The Enemy isn't Big Pharma. It's the FDA and Regulators who won't allow you to test experimental therapies on yourself (or your dog). Even if it's life or death.

By Ryan Bethencourt
Aberrant mRNA Variants Drive Endometriosis Cell Growth
NewsMar 15, 2026

Aberrant mRNA Variants Drive Endometriosis Cell Growth

A recent study published in a leading gynecologic journal reveals that aberrant mRNA splice variants are a driving force behind the uncontrolled proliferation of endometriotic cells. Researchers identified a set of up‑regulated transcripts that activate the PI3K/AKT pathway, boosting lesion...

By Bioengineer.org
Single Rapamycin Dose Boosts Brain Glucose, Cuts Synaptic Density
SocialMar 15, 2026

Single Rapamycin Dose Boosts Brain Glucose, Cuts Synaptic Density

Single-dose rapamycin increases brain glucose metabolism but reduces synaptic density in Long-Evans rats [One week after intraperitoneal administration of rapamycin (8 mg/kg) 👨‍⚕️] https://t.co/6JhcZYS01h https://t.co/wruacgIvFM

By David Barzilai, MD PhD
Engineering Smarter, Healthier Babies Through Embryo Selection
SocialMar 15, 2026

Engineering Smarter, Healthier Babies Through Embryo Selection

The man engineering smarter, healthier babies before they're born: Jonathan Anomaly. This philosopher-turned-biotech founder says the future of your child's health starts at the embryo. Here are 9 things you need to know about embryo selection: https://t.co/XVQF5le4bE

By John Cumbers
Transcutaneous CO2 Monitoring: The Future Standard of Care?
NewsMar 15, 2026

Transcutaneous CO2 Monitoring: The Future Standard of Care?

Transcutaneous carbon dioxide (tcCO₂) monitoring is emerging as a viable alternative to arterial blood gases and end‑tidal CO₂ in neonatal and pediatric intensive care. Recent Pediatric Research data show a strong correlation between tcCO₂ readings and PaCO₂ in stable patients,...

By Bioengineer.org
Insulin-Like Peptide Trades Combat for Survival in Beetles
SocialMar 15, 2026

Insulin-Like Peptide Trades Combat for Survival in Beetles

Insulin-like peptide has antagonistic pleiotropic effects on male combat traits and survival traits in an armed beetle https://t.co/7Re0I2vcDW

By David Barzilai, MD PhD
Techie Shrinks Dog's Tumor by Half After Using ChatGPT to Design ‘First Personalized Cancer Vaccine’
NewsMar 15, 2026

Techie Shrinks Dog's Tumor by Half After Using ChatGPT to Design ‘First Personalized Cancer Vaccine’

Australian tech enthusiast Paul Conyngham used ChatGPT and AlphaFold to design a personalized mRNA vaccine for his dog Rose, whose tumor was genetically sequenced at UNSW. The AI‑assisted workflow identified mutations and suggested therapeutic targets, enabling a custom vaccine administered...

By Mint – Technology (India)
Scientists Discover ALS Protein that Links DNA Repair to Cancer and Dementia
NewsMar 15, 2026

Scientists Discover ALS Protein that Links DNA Repair to Cancer and Dementia

Researchers at Houston Methodist identified the ALS‑linked protein TDP43 as a regulator of DNA mismatch repair genes. Dysregulated TDP43—whether under‑ or over‑expressed—triggers abnormal repair activity that destabilizes the genome. Analysis of large cancer datasets revealed that tumors with high TDP43...

By ScienceDaily – Neuroscience
Japan Becomes First to Approve Stem Cell Therapies for Parkinson’s and Heart Failure
NewsMar 15, 2026

Japan Becomes First to Approve Stem Cell Therapies for Parkinson’s and Heart Failure

Japan has become the first country to grant conditional approval for two regenerative medicines that use induced pluripotent stem cells—AMCHEPRY for Parkinson’s disease and RiHEART for severe heart failure. The Parkinson’s therapy implants dopamine‑producing neurons into the brain, while the...

By Medical News Today
Minimally Invasive Clearing Media Enables Deep Live Brain Imaging
SocialMar 14, 2026

Minimally Invasive Clearing Media Enables Deep Live Brain Imaging

Isotonic and minimally invasive optical clearing media for live cell imaging ex vivo and in vivo "Here we develop minimally invasive optical clearing media for fluorescence imaging of live mammalian tissues.... SeeDB-Live minimally affects neuronal electrophysiological properties and sensory responses in...

By David Barzilai, MD PhD
Weekly Biotech Roundup: Top Insights Curated by BiopharmIQ
SocialMar 14, 2026

Weekly Biotech Roundup: Top Insights Curated by BiopharmIQ

Here is my favourite weekly 🧵- made by my dear friend @BiopharmIQ. This post is a comprehensive recap of the past week in BioTech and gathers the best related posts written by some of the smartest & brightest 𝕏 Bio...

By Yair Einhorn
Q&A: Gassing up Bioengineered Materials for Wound Healing
NewsMar 14, 2026

Q&A: Gassing up Bioengineered Materials for Wound Healing

Penn State researchers have engineered a new class of granular aerogel scaffolds (GAS) that allow precise control of pore architecture using protein‑based microparticles. The tunable, oxygen‑rich material demonstrated superior cell infiltration and rapid vascularization in both laboratory assays and mouse...

By Medical Xpress
Turning Personal Loss Into Open Cancer Vaccine Platform
SocialMar 14, 2026

Turning Personal Loss Into Open Cancer Vaccine Platform

Paul's story developing a cancer vaccine for Rosie inspired me. I'm going to build something so that EVERYONE can do the same thing. My dog Lady died of hemagiosarcoma and I wish I'd been able to save her too ETA - hopefully a...

By Ryan Bethencourt
Chris Bradley: Better Science for Longevity
PodcastMar 14, 20260 min

Chris Bradley: Better Science for Longevity

In this episode, host Rizim Tom chats with Chris Bradley of MatterBio about the science of longevity, focusing on how genomic damage drives the hallmarks of aging. Bradley explains that while cells constantly renew, DNA damage from internal sources like...

By Razib Khan: Unsupervised Learning
Micro-Cages Enable Precise Manipulation of Cell Clusters
SocialMar 14, 2026

Micro-Cages Enable Precise Manipulation of Cell Clusters

These micro-cages are designed to hold and manipulate tiny cell clusters in miniaturized lab-on-a-chip devices. https://spectrum.ieee.org/lab-on-a-chip-grippers?share_id=9241061

By IEEE Spectrum Threads
EGFR Vs. ALK: How Molecular Profiling Defines Lung Cancer Treatment
BlogMar 14, 2026

EGFR Vs. ALK: How Molecular Profiling Defines Lung Cancer Treatment

Comprehensive molecular profiling of two stage IV NSCLC patients revealed distinct driver alterations—an EGFR exon 19 deletion in one and an EML4‑ALK fusion in the other—prompting personalized first‑line therapy with osimertinib and alectinib respectively. Both patients experienced rapid symptomatic improvement and enhanced...

By KevinMD
Re: Standard Chemoradiotherapy with Concurrent and Adjuvant Camrelizumab in Patients with High Risk Nasopharyngeal Carcinoma: Multicentre, Randomised, Open Label, Phase...
NewsMar 14, 2026

Re: Standard Chemoradiotherapy with Concurrent and Adjuvant Camrelizumab in Patients with High Risk Nasopharyngeal Carcinoma: Multicentre, Randomised, Open Label, Phase...

A phase‑3 BMJ trial reported that adding camrelizumab to standard chemoradiotherapy improved 36‑month progression‑free, distant‑metastasis‑free and locoregional‑recurrence‑free survival in high‑risk nasopharyngeal carcinoma. The protocol combined two concurrent cycles with 17 adjuvant cycles, yet only 61.9% of patients completed the full...

By BMJ (Latest)
Zydus Lifesciences’ Anaemia Drug Desidustat Gets China Approval
NewsMar 14, 2026

Zydus Lifesciences’ Anaemia Drug Desidustat Gets China Approval

Zydus Lifesciences has received NMPA approval for its oral anaemia drug Desidustat, targeting renal anaemia in adult chronic kidney disease patients who are not on dialysis. The therapy, a hypoxia‑inducible factor‑prolyl hydroxylase inhibitor, demonstrated efficacy and safety in Chinese Phase III...

By The Hindu BusinessLine – Companies
First Human Age‑Reversal Trial Targets Whole‑Body Reset
SocialMar 14, 2026

First Human Age‑Reversal Trial Targets Whole‑Body Reset

The first human age-reversal trial is officially happening. But before the FDA cleared it, Harvard professor David Sinclair had to pull off a mice experiment most scientists thought was impossible: "These mice had their optic nerve regenerated. We were able to...

By John Cumbers
Drug Patents: Near-Term Generic Threat, Mid-Term Safeguards, Tirzepat
SocialMar 14, 2026

Drug Patents: Near-Term Generic Threat, Mid-Term Safeguards, Tirzepat

AI: Short-Term Cliffs (0-3 years remaining): Drugs like sacubitril/valsartan, dapagliflozin, pembrolizumab, ocrelizumab, daratumumab, and apixaban face imminent generic/biosimilar pressure Mid-Term Protection (4-7 years): Risankizumab and dupilumab have solid runway, supported by ongoing label expansions. Long-Term (8+ years): Tirzepatide's robust patents position it...

By Peter Suzman
YolTech Therapeutics Receives FDA Clearance to Initiate Phase 2/3 Study of In Vivo Gene-Editing Therapy YOLT-202 in Alpha-1 Antitrypsin Deficiency...
BlogMar 14, 2026

YolTech Therapeutics Receives FDA Clearance to Initiate Phase 2/3 Study of In Vivo Gene-Editing Therapy YOLT-202 in Alpha-1 Antitrypsin Deficiency...

YolTech Therapeutics announced FDA approval of its IND for YOLT-202, an in vivo adenine base‑editing therapy targeting Alpha‑1 Antitrypsin Deficiency. The clearance permits an open‑label, single‑dose Phase 2/3 expansion study across the U.S. and other regions. In the ongoing first‑in‑human trial,...

By HealthTech HotSpot
FoxO3a Boost in Dentate Gyrus Eases Stress‑induced Depression
SocialMar 14, 2026

FoxO3a Boost in Dentate Gyrus Eases Stress‑induced Depression

Overexpression of FoxO3a in the dentate gyrus alleviates CUS-induced anxiety- and depression-like behaviors and cognitive impairment https://t.co/p2t18NRkew

By David Barzilai, MD PhD
A Lab Mistake at Cambridge Reveals a Powerful New Way to Modify Drug Molecules
NewsMar 14, 2026

A Lab Mistake at Cambridge Reveals a Powerful New Way to Modify Drug Molecules

Cambridge chemists have unveiled a light‑driven “anti‑Friedel‑Crafts” reaction that forms carbon‑carbon bonds using only LED illumination at ambient temperature. The metal‑free method allows precise, late‑stage modifications of complex drug molecules, cutting months of multistep synthesis. Tested on a broad set...

By ScienceDaily – Nanotechnology
Immune Checkpoint Dysregulation Drives Pediatric Bronchiolitis Severity
NewsMar 14, 2026

Immune Checkpoint Dysregulation Drives Pediatric Bronchiolitis Severity

A new multicenter study links dysregulated immune checkpoint pathways, especially PD‑1/PD‑L1 and CTLA‑4, to heightened severity in pediatric bronchiolitis. Researchers measured checkpoint molecule expression in airway samples from 312 infants and found that higher PD‑1 levels correlated with increased IL‑6,...

By Bioengineer.org
EpiAge‑R Integrates Epigenetic Clocks, Resilience, and Multi‑omics Ageing
SocialMar 14, 2026

EpiAge‑R Integrates Epigenetic Clocks, Resilience, and Multi‑omics Ageing

Epigenetic Clocks, Resilience, and Multi-Omics Ageing: A Review and the EpiAge-R Conceptual Framework The hierarchical architecture of the EpiAge-R framework... https://t.co/YpwDdLI7wo https://t.co/Uid3kNzDHr

By David Barzilai, MD PhD
Pretzel Therapeutics Presents PX578 Data Supporting POLG Disease Treatment
NewsMar 14, 2026

Pretzel Therapeutics Presents PX578 Data Supporting POLG Disease Treatment

Pretzel Therapeutics presented preclinical data for its investigational small‑molecule PX578 at the 2026 MDA Clinical and Scientific Conference. The drug is designed to activate the mitochondrial DNA polymerase gamma (POLG) and restore mitochondrial DNA levels in patients with mitochondrial DNA...

By Longevity.Technology
What’s New Pussycat? FDA Assists Drug Sponsors Requesting New Clinical Investigation Exclusivity
NewsMar 14, 2026

What’s New Pussycat? FDA Assists Drug Sponsors Requesting New Clinical Investigation Exclusivity

The FDA released draft Q&A guidance that clarifies how drug sponsors can qualify for three‑year non‑patent exclusivity by conducting a “new clinical investigation.” It defines a new study as a human, non‑bioavailability trial whose results have not been previously relied...

By JD Supra – Legal Tech
Rare Disease Spotlight: Friedreich Ataxia Moves Beyond Mitochondrial Bandages
NewsMar 14, 2026

Rare Disease Spotlight: Friedreich Ataxia Moves Beyond Mitochondrial Bandages

Friedreich ataxia (FA) received its first FDA‑approved therapy in 2023 when omaveloxolone, marketed as Skyclarys, earned accelerated approval. Biogen’s $7.3 billion acquisition of Reata Pharmaceuticals secured the drug and highlighted the market’s appetite for rare‑disease assets. Skyclarys works by activating the...

By BioCentury
Network-Based Prediction of Drug Combinations with Quantum Annealing
NewsMar 13, 2026

Network-Based Prediction of Drug Combinations with Quantum Annealing

The study introduces a quantum‑annealing algorithm that predicts effective drug combinations by casting the problem as a quadratic unconstrained binary optimisation (QUBO). It leverages the network‑medicine concept of disease modules and the “Complementary Exposure” principle, which seeks drugs that hit...

By Research Square – News/Updates
Real-Time PCR–Based Detection of Mycoplasma Agalactiae in Sheep Bulk Tank Milk to Support Flock-Level Epidemiology
NewsMar 13, 2026

Real-Time PCR–Based Detection of Mycoplasma Agalactiae in Sheep Bulk Tank Milk to Support Flock-Level Epidemiology

A real‑time PCR assay for detecting Mycoplasma agalactiae in sheep bulk‑tank milk was developed and validated, showing high specificity and sensitivity. The test was deployed across more than 900 dairy sheep farms in Sardinia, revealing widespread but generally low‑level prevalence...

By Research Square – News/Updates
Horse IVF Milestone in Florida: Frozen-Thawed Sperm Fertilizes an Egg
NewsMar 13, 2026

Horse IVF Milestone in Florida: Frozen-Thawed Sperm Fertilizes an Egg

University of Florida researchers have achieved the first successful in‑vitro fertilization of a horse egg using frozen‑thawed sperm. The study showed that frozen‑thawed stallion sperm, after undergoing stress‑induced capacitation, fertilized the oocyte more effectively than fresh or chilled sperm. This...

By Phys.org – Biotechnology
Adenine Methylation Forms New Linear Brain Aging Clock
SocialMar 13, 2026

Adenine Methylation Forms New Linear Brain Aging Clock

A completely novel axis of epigenetic aging. N6-methyldeoxyadenosine (N6medA), i.e. NOT the usual 5 methyl cytosine, increases linearly with age in human prefrontal cortex (r=0.95). Genome-wide profiling reveals age-associated ADENINE methylation changes reminiscent of classic CpG based epigenetic clocks. Abdur...

By Steve Horvath, PhD
Vaccination Boosts Survival in Multiple Myeloma Patients
SocialMar 13, 2026

Vaccination Boosts Survival in Multiple Myeloma Patients

Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML https://t.co/kUQeRmdKWV #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx https://t.co/L7r9caCcGN

By Mike Thompson, MD PhD
Quantifying Pathway Identifiability Under Partial Metabolomics for Measurement Prioritization
NewsMar 13, 2026

Quantifying Pathway Identifiability Under Partial Metabolomics for Measurement Prioritization

The study introduces an operator‑based framework to assess pathway identifiability when metabolite coverage is incomplete. It aligns condition‑specific pathway graphs using a Johnson‑Lindenstrauss stabilized fused Gromov‑Wasserstein (JL‑FGW) operator and quantifies ambiguity via a composite functional that blends transport entropy, alignment...

By Research Square – News/Updates
MRD‑Negative Patients May Stop Myeloma Maintenance Therapy
SocialMar 13, 2026

MRD‑Negative Patients May Stop Myeloma Maintenance Therapy

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP) - @bdermanmd et al. @ajjakubowiak #ASCO24 Abstract 106 https://t.co/FBTY7SnCxK #NCT04108624 #mmsm #mmMRD

By Mike Thompson, MD PhD
ODAC Backs MRD as Early Endpoint for Myeloma Approvals
SocialMar 13, 2026

ODAC Backs MRD as Early Endpoint for Myeloma Approvals

A Historic Turning Point: ODAC Unanimously Votes [4/12/24] in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments [Apr 18, 2024] @IMFmyeloma https://t.co/eDOgIrpVeR #mmMRD #mmsm #ctsm @FDAOncology https://t.co/W3vwHRTzhE

By Mike Thompson, MD PhD
No Broad Autism Approval for Leucovorin, Despite FDA Commissioner’s Prior Suggestions
BlogMar 13, 2026

No Broad Autism Approval for Leucovorin, Despite FDA Commissioner’s Prior Suggestions

The FDA on March 10 expanded leucovorin’s label to cover a very rare genetic folate‑transport disorder, not autism. Earlier, Commissioner Marty Makary suggested the drug could help “hundreds of thousands of kids” with autism, creating expectations of a broad approval. FactCheck.org...

By FactCheck.org
Testing Ubiquitin Promoter for Stable Petunia Transformation
SocialMar 13, 2026

Testing Ubiquitin Promoter for Stable Petunia Transformation

Alright, Alice 24-0001 petunia bits co-culturing with Agribacterium strain Gv3101 carrying a PcUBI4::RUBY::THSP construct. Testing out this ubiquitin promoter for stable transformation to avoid silencing. These will bake at 30°C until Monday and then transfered to selection. 🤞 https://t.co/SO1EKELMgU

By Sebastian Cocioba
How Dompé Is Innovating in Neuro-Ophthalmology with the FDA’s CNPV Program
BlogMar 13, 2026

How Dompé Is Innovating in Neuro-Ophthalmology with the FDA’s CNPV Program

Dompe, a privately owned biopharma, is advancing an intranasal nerve growth factor (NGF) therapy to treat non‑arteritic anterior ischemic optic neuropathy (NAION), a leading cause of sudden vision loss affecting roughly 6,000 U.S. patients annually. The approach leverages NGF’s neuroprotective...

By Xtalks – Biotech Blogs
Bacterial Strain Breaks Decades-Old Bottleneck in Chemotherapy Drug Manufacturing
NewsMar 13, 2026

Bacterial Strain Breaks Decades-Old Bottleneck in Chemotherapy Drug Manufacturing

An international research team has engineered a bacterial strain that boosts doxorubicin output by 180% compared with current industrial methods, overcoming three long‑standing bottlenecks—insufficient redox partners, drug‑binding “sponge” proteins, and suboptimal enzyme positioning. The findings, published in Nature Communications, detail...

By Phys.org – Biotechnology
Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits
NewsMar 13, 2026

Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits

During the COVID‑19 pandemic, vaccine makers pledged not to enforce mRNA‑related patents, but that restraint has ended, sparking a wave of litigation over lipid nanoparticle (LNP) and mRNA payload technologies. Major cases include Alnylam’s suits against Pfizer and BioNTech, Arbutus’s...

By JD Supra – Legal Tech
University of Calgary Researchers Use AI to Hunt New Treatments for Cattle Parasites
NewsMar 13, 2026

University of Calgary Researchers Use AI to Hunt New Treatments for Cattle Parasites

University of Calgary researchers have secured a $1.4 million NSERC grant to apply AI‑driven genomics in the hunt for new anti‑parasitic drugs targeting roundworms in beef cattle. By sequencing helminth genomes and screening large chemical libraries, the team has already identified...

By BetaKit (Canada)